001     212418
005     20240229162310.0
024 7 _ |a 10.3390/medicina59010127
|2 doi
024 7 _ |a pmid:36676751
|2 pmid
024 7 _ |a 1010-660X
|2 ISSN
024 7 _ |a 1648-9144
|2 ISSN
024 7 _ |a altmetric:141630186
|2 altmetric
037 _ _ |a DKFZ-2023-00137
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Chmielewski, Witold X
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Pre-Surgery Patient Health Contributes to Aggravated Sino-Nasal Outcome and Quality of Life after Pituitary Adenomectomy.
260 _ _ |a Kaunas
|c 2023
|b Kaunas Univ. of Medicine
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1674469688_15650
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Objectives: The transphenoidal bi-nostril endoscopic resection of pituitary adenomas is regarded as a minimally invasive treatment nowadays. However, sino-nasal outcome and health-related quality of life (HRQoL) might still be impaired after the adenomectomy, depending on patients' prior medical history and health status. A systematic postoperative comparison is required to assess differences in perceived sino-nasal outcome and HRQoL. Methods: In this single-center observational study, we collected data from 81 patients, operated between August 2016 and August 2021, at a 3-6-month follow-up after adenomectomy. We employed the sino-nasal outcome test for neurosurgery (SNOT-NC) and the HRQoL inventory Short Form (SF)-36 to compare sino-nasal and HRQoL outcome in patients with or without allergies, previous nose surgeries, presence of pain, snoring, sleep apnea, usage of continuous positive airway pressure (cpap), and nose drop usage. Results: At the 3-6-month follow-up, patients with previous nasal surgery showed overall reduced subjective sino-nasal health, increased nasal and ear/head discomfort, increased visual impairment, and decreased psychological HRQoL (all p ≤ 0.026) after pituitary adenomectomy. Patients with pain before surgery showed a trend-level aggravated physical HRQoL (p = 0.084). Conclusion: Our data show that patients with previous nasal surgery have an increased risk of an aggravated sino-nasal and HRQoL outcome after pituitary adenomectomy. These patients should be thoroughly informed about potential consequences to induce realistic patient expectations. Moreover, the study shows that patients with moderately severe allergies, snoring, and sleep apnea (± cpap) usually do not have to expect a worsened sino-nasal health and HRQoL outcome.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a adenomectomy
|2 Other
650 _ 7 |a health-related quality of life
|2 Other
650 _ 7 |a pituitary adenoma
|2 Other
650 _ 7 |a pre-surgery patient health
|2 Other
650 _ 7 |a sino-nasal health
|2 Other
700 1 _ |a Walbrodt, Sebastian
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Rauschenbach, Laurèl
|0 0000-0001-8348-4298
|b 2
700 1 _ |a Chihi, Mehdi
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Gembruch, Oliver
|0 0000-0002-0054-1611
|b 4
700 1 _ |a Darkwah Oppong, Marvin
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Schroer, Sebastian
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Wrede, Karsten H
|0 0000-0001-7076-3503
|b 7
700 1 _ |a Dammann, Philipp
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Jabbarli, Ramazan
|0 0000-0002-8356-6629
|b 9
700 1 _ |a Kreitschmann-Andermahr, Ilonka
|0 0000-0002-6389-0261
|b 10
700 1 _ |a Sato, Taku
|0 0000-0002-4303-0600
|b 11
700 1 _ |a Unger, Nicole
|b 12
700 1 _ |a Mattheis, Stefan
|b 13
700 1 _ |a Sure, Ulrich
|0 0000-0002-9073-1821
|b 14
700 1 _ |a Ahmadipour, Yahya
|0 0000-0003-3759-8301
|b 15
773 _ _ |a 10.3390/medicina59010127
|g Vol. 59, no. 1, p. 127 -
|0 PERI:(DE-600)2088820-X
|n 1
|p 127
|t Medicina
|v 59
|y 2023
|x 1010-660X
909 C O |o oai:inrepo02.dkfz.de:212418
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 0000-0001-8348-4298
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 0000-0002-0054-1611
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 0000-0001-7076-3503
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 0000-0002-8356-6629
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 0000-0002-6389-0261
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 0000-0002-4303-0600
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 0000-0002-9073-1821
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 0000-0003-3759-8301
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2023
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-09-26T09:52:22Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-29
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-29
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:01:12Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:01:12Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:01:12Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MEDICINA-LITHUANIA : 2022
|d 2023-10-24
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-24
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK ED ES zentral
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21